In recent years, an increasing body of research has indicated that HDAC inhibitors, such as tubastatin and vorinostat, play a significant role in ameliorating pulmonary fibrosis by correcting aberrant acetylation [43,44]. This evidence concerns the gene HDAC9 and pulmonary fibrosis.